Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 11/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glpg-0259 SCHEMBL1570157 | 0.83 | MAPKAPK5 (0.49) | SYKMAPKAPK5BTKTLR9TLR8 | |
| Glpg-0259 SCHEMBL12661679 | 0.83 | MAPKAPK5 (0.49) | SYKMAPKAPK5BTKTLR9TLR8 | |
| Glpg-0259 SCHEMBL1889564 | 0.83 | MAPKAPK5 (0.49) | SYKMAPKAPK5BTKTLR9TLR8 | |
| SCHEMBL2387713 | 0.81 | SYK (0.43) | SYKMAPKAPK5BTKTLR9TLR8 | |
| SCHEMBL1888880 | 0.78 | SYK (0.46) | SYKMAPKAPK5TLR9TLR8TLR7 | |
| SCHEMBL1887992 | 0.78 | SYK (0.46) | SYKMAPKAPK5TLR9TLR8TLR7 | |
| SCHEMBL1570061 | 0.77 | MAPKAPK5 (0.49) | SYKMAPKAPK5BTKTTKPRKCB | |
| SCHEMBL2389685 | 0.76 | MAPKAPK5 (0.64) | SYKMAPKAPK5TLR9TLR8TLR7 | |
| SCHEMBL1570224 | 0.76 | MAPKAPK5 (0.42) | SYKMAPKAPK5TTK | |
| SCHEMBL2390949 | 0.75 | SYK (0.44) | SYKMAPKAPK5TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | SYK 3339/4885MAPKAPK5 131/4885BTK 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.